PT  - JOURNAL ARTICLE
AU  - Kraposhina, Angelina
AU  - Demko, Irina
AU  - Gordeeva, Natalya
AU  - Soloveva, Irina
AU  - Mamaeva, Marina
AU  - Sobko, Elena
TI  - Results of vaccination against pneumococcal infection in patients with chronic lung diseases
AID  - 10.1183/13993003.congress-2019.PA2896
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA2896
VI  - 54
IP  - suppl 63
4099  - https://publications.ersnet.org//content/54/suppl_63/PA2896.short
4100  - https://publications.ersnet.org//content/54/suppl_63/PA2896.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Aim: to study effectiveness of specific prevention of pneumococcal infection in patients with chronic lung diseases.Materials and Methods: to assess the clinical effectiveness of vaccination, special questionnaire was developed, which included an assessment of anamnesis during the year preceding vaccination and anamnesis of the underlying disease during the year after vaccination. 881 patients with chronic lung diseases were vaccinated.Results: vaccination against pneumococcus in patients with chronic lung diseases has significantly reduced the number of exacerbations of the underlying disease in patients aged 56-60years(RR=0.3(95%CI:0.12-0.73),61-65years(RR=0.3(95%CI:0.12-0.73) and 66-70years(RR=0.17(95%CI:0.06-0.49)(p<0.05). There is also a positive trend with regard to hospitalizations for decompensation of the underlying disease: for the year after vaccination, no hospitalization cases were registered in all groups. There was also a significant decrease in the incidence of acute respiratory diseases in patients of almost all age groups:56-60 years RR=0.13(95%CI:0.04-0.41);61-65years RR=0.35(95%CI:0.16-0.76);66-70years RR=0.13(95%CI:0.03-0.53); 76-80 years RR=0.06 (95%CI:0.01-0.43)(p<0.05). The number of episodes of pneumonia in this group before and after vaccination did not differ significantly.Conclusions: the results indicate a high efficiency of vaccination against pneumococcal infection in patients with chronic lung disease: in all groups a decrease in the incidence of respiratory infections, reduction in the number of exacerbations of the underlying disease and hospitalizations for exacerbations.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2896.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).